IMPEL PHARMACEUTICALS INC (IMPL)

US45258K1097 - Common Stock

0.2411  -0.17 (-41.79%)

After market: 0.22 -0.02 (-8.75%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
670K12.65M
1,788.06%		29.274M
131.42%
EBITDA
YoY % growth
-44.25M
-8.32%		-70.4M
-59.10%		-81.88M
-16.31%		-70.278M
14.17%		N/AN/AN/AN/AN/A
EBIT
YoY % growth
-45.33M
-9.04%		-71.49M
-57.71%		-83.08M
-16.21%		-71.094M
14.43%
Operating Margin
N/A-10,670.15%-656.76%-242.86%
EPS
YoY % growth
N/A-3.95-4.54
-14.94%		-1.61
64.50%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q3 / 23 Q4 / 23 Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24
EPS
Q2Q % growth		-0.37
71.97%
Revenue
Q2Q % growth		8.16M
164.94%
EBITDA
Q2Q % growth		N/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth		-13.872M
34.69%		N/AN/AN/AN/A

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2023
Q2Q % growth		 -0.58
55.73%		-0.37-0.21-57.95%
Q2 2023
Q2Q % growth		 -0.86
21.10%		-0.67-0.19-28.72%
Q1 2023
Q2Q % growth		 -1.27
-8.55%		-0.92-0.35-38.34%
Q4 2022
Q2Q % growth		 -0.97
9.35%		-1.140.1714.63%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q2 2023
Q2Q % growth		 6.58M
135.00%		6.63M-50K-0.75%
Q1 2023
Q2Q % growth		 4.37M
148.30%		5.848M-1.478M-25.27%
Q4 2022
Q2Q % growth		 5.01M
763.79%		5.065M-55K-1.09%
Q3 2022
Q2Q % growth		 3.08M
3,322.22%		5.942M-2.862M-48.17%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% 0% 0% 0%
Revenue0% 99900% 0% 0%